Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
Janssen Research & Development, LLC
Remo Panaccione; Brian G Feagan; Anita Afzali; David T Rubin; Walter Reinisch; Julián Panés; Silvio Danese; Tadakazu Hisamatsu; Natalie A Terry; Leonardo Salese; Rian Van Rampelbergh; Aparna Sahoo; Marion L Vetter; Jacqueline Yee; Chenglong Han; Mary Ellen Frustaci; Kitty Y Y Wan; Zijiang Yang; Jewel Johanns; Jane M Andrews; Geert R D'Haens; Bruce E Sands; GALAXI 2 & 3 Study Group